$ cat ./records/awarded-82-9-million-to-the-international-aids-vaccine-initiative-2004.txt
Awarded $82.9 million to the International AIDS Vaccine Initiative to accelerate HIV vaccine research
[RECORD.TXT] · cat --full
The Gates Foundation awarded $82.9 million to the International AIDS Vaccine Initiative (IAVI) to accelerate research toward an effective HIV vaccine. HIV remained one of the most scientifically challenging vaccine targets due to its rapid mutation and ability to evade immune responses. The grant was one of the largest single private contributions to HIV vaccine research at the time, supporting clinical trials of novel vaccine candidates across Africa and Asia where HIV burden was highest.
Source: https://www.iavi.org/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Awarded $35 million to Zambia's national malaria control program to scale up bed net distribution
Next →
Funded the PATH Malaria Vaccine Initiative with $107.6 million to advance GlaxoSmithKline's RTS,S vaccine
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.